Synonyms: afabicin desphosphono | AFN-1252 | AFN-12520000 | DEBIO-1452 | DEBIO1452
Compound class:
Synthetic organic
Comment: DEBIO 1452 (previously AFN-1252) is the active metabolite of afabicin (DEBIO 1450) [3]. It is an inhibitor of bacterial Fabl, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II) [1-2]. It specifically targets staphylococci without significant activity against other Gram +ve or Gram -ve species [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
The prodrug (afabicin) has been evaluated as an antibacterial for skin, bone and joint infections. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00014690 | ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Phase 2 Interventional | National Cancer Institute (NCI) |